Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura L Poling

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
BMC Biology|January 21, 2004
The colonization of land by animals: molecular phylogeny and divergence times among arthropodsDavide Pisani, Laura L Poling, Maureen Lyons-Weiler, et al.
Pigment Cell & Melanoma Research|July 17, 2008
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineageSatoru Yokoyama, Erez Feige, Laura L Poling, et al.
Genes & Development|December 6, 2008
Chromatin structure analyses identify miRNA promotersFatih Ozsolak, Laura L Poling, Zhengxin Wang, et al.
Cancer Research|August 17, 2010
GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signalingAilin Bai, Kristan Meetze, Nhi Y Vo, et al.
Molecular Cancer Therapeutics|March 16, 2021
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander EffectAleksandr V Yurkovetskiy, Natalya D Bodyak, Mao Yin, et al.
Molecular Cancer Therapeutics|March 16, 2021
The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2bNatalya D Bodyak, Rebecca Mosher, Aleksandr V Yurkovetskiy, et al.
Journal of Medicinal Chemistry|November 24, 2025
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9Katrina L Jackson, Ning Yin, Roman V Agafonov, et al.
Cancer Research|October 28, 2025
CFT1946 is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader that Overcomes BRAF Inhibitor ResistanceBridget T Kreger, Yanke Liang, Nicole M Reilly, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
BMC Biology|January 21, 2004
The colonization of land by animals: molecular phylogeny and divergence times among arthropodsDavide Pisani, Laura L Poling, Maureen Lyons-Weiler, et al.
Pigment Cell & Melanoma Research|July 17, 2008
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineageSatoru Yokoyama, Erez Feige, Laura L Poling, et al.
Genes & Development|December 6, 2008
Chromatin structure analyses identify miRNA promotersFatih Ozsolak, Laura L Poling, Zhengxin Wang, et al.
Cancer Research|August 17, 2010
GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signalingAilin Bai, Kristan Meetze, Nhi Y Vo, et al.
Molecular Cancer Therapeutics|March 16, 2021
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander EffectAleksandr V Yurkovetskiy, Natalya D Bodyak, Mao Yin, et al.
Molecular Cancer Therapeutics|March 16, 2021
The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2bNatalya D Bodyak, Rebecca Mosher, Aleksandr V Yurkovetskiy, et al.
Journal of Medicinal Chemistry|November 24, 2025
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9Katrina L Jackson, Ning Yin, Roman V Agafonov, et al.
Cancer Research|October 28, 2025
CFT1946 is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader that Overcomes BRAF Inhibitor ResistanceBridget T Kreger, Yanke Liang, Nicole M Reilly, et al.
Pageof 1